Thailand medical researchers find that Huperzine A from Huperzia Serrata Moss can help combat Alzheimer’s disease

Thailand Medical: Alzheimer's disease (AD) continues to pose a significant challenge globally, especially with no known cure. But a recent breakthrough by Thai researchers offers hope. A study led by researchers from several prominent Thai institutions, including the Chulabhorn Graduate Institute, Chulabhorn Royal Academy, and Mahidol University, explores how Huperzine A, a compound extracted from the moss Huperzia serrata, could potentially slow down the progression of Alzheimer's. This Thailand Medical news report delves into the details of this promising study, which reveals that Huperzine A can help regulate critical processes involved in Alzheimer’s disease.


Thailand medical researchers find that Huperzine A from Huperzia Serrata Moss can
help combat Alzheimer’s disease

Understanding Alzheimer's Disease: The Need for New Treatments
Alzheimer’s disease is a progressive neurological disorder that leads to memory loss and cognitive decline. The disease is largely characterized by the formation of amyloid plaques and neurofibrillary tangles in the brain. These plaques are made up of a protein called amyloid-beta (Aβ), while the tangles consist of tau proteins that are improperly folded and phosphorylated. As more people reach old age, Alzheimer’s disease is becoming increasingly common, placing immense pressure on healthcare systems worldwide. Although current treatments aim to alleviate symptoms, none have been able to halt or reverse the disease.
 
In light of this, the research conducted by Thai institutions is a breakthrough. The researchers found that Huperzine A can regulate proteins involved in amyloid and tau processes, potentially preventing the buildup of toxic proteins that lead to Alzheimer’s. The Thai researchers have high hopes for this compound.
 
What is Huperzine A?
Huperzine A is a naturally occurring compound extracted from the moss Huperzia serrata. The compound has long been used in traditional Chinese medicine to improve memory and treat dementia. Recent scientific investigations have confirmed its neuroprotective properties, especially in relation to Alzheimer's disease. Researchers believe that Huperzine A works by modulating the levels of certain proteins that contribute to the accumulation of amyloid plaques and neurofibrillary tangles.
 
The study aimed to investigate whether Huperzine A could influence the amyloid precursor protein (APP) and tau protein, both of which are central to Alzheimer's disease development.
 
Key Findings of the Study
The Thai research team explored how Huperzine A regulates two critical pathways in Alzheimer's disease: the amyloidogenic and nonamyloidogenic pathways. These pathways control how APP is processed, ultimately determining whether toxic amyloid-beta accumulates in the brain or not.
 
The study showed that Huperzine A significantly lowered the levels of two enzymes, BACE1 an d presenilin-1 (PS1), which are involved in the production of toxic amyloid-beta peptides. On the other hand, the compound increased the levels of ADAM10, an enzyme involved in the nonamyloidogenic pathway, which helps prevent the buildup of amyloid plaques. Furthermore, Huperzine A reduced the phosphorylation of tau proteins, preventing their aggregation into neurofibrillary tangles, a hallmark of Alzheimer’s disease.
 
These findings are exciting because they suggest that Huperzine A not only prevents the formation of amyloid plaques but also tackles the issue of tau protein aggregation. This two-fold mechanism could make Huperzine A a potent therapeutic agent for Alzheimer's disease.
 
Mechanisms of Action: Amyloid and Tau Regulation
Huperzine A’s effects on APP proteolysis were analyzed in SH-SY5Y neuroblastoma cells, a common model for studying Alzheimer's disease. The researchers found that the compound reduced the expression of BACE1 and PS1 while increasing the levels of ADAM10. This shift from amyloidogenic to nonamyloidogenic processing means that less amyloid-beta is produced, and the brain's ability to clear this harmful protein is enhanced.
 
In addition, Huperzine A was found to decrease the levels of phosphorylated tau, a key factor in the formation of neurofibrillary tangles. This reduction in tau phosphorylation was linked to the inhibition of glycogen synthase kinase-3β (GSK3β), an enzyme that plays a crucial role in the abnormal phosphorylation of tau proteins. By inhibiting GSK3β, Huperzine A helps maintain normal tau protein function, preventing their accumulation and the resulting neuronal damage.
 
The Study’s Experimental Methods
The study combined both computational and experimental methods to analyze the effects of Huperzine A. Through molecular docking, the researchers demonstrated how Huperzine A binds to the active site of BACE1, inhibiting its activity. Western blotting techniques further confirmed that the compound reduces the protein levels of BACE1, PS1, and phosphorylated tau, while increasing the levels of ADAM10 and APP-C83, a product of the nonamyloidogenic pathway.
 
The researchers treated neuroblastoma cells with varying concentrations of Huperzine A to observe its effects on APP and tau protein processing. The results were consistent across different concentrations, demonstrating that even small doses of Huperzine A could have significant effects on Alzheimer's disease-related processes.
 
The Potential for Huperzine A as a Therapeutic Agent
While current Alzheimer's treatments focus on managing symptoms, the findings from this study suggest that Huperzine A could be used as a preventive treatment. By modulating APP processing and tau phosphorylation, the compound could slow or even prevent the onset of Alzheimer’s disease. This is a major step forward, as it shifts the focus from treating the symptoms of Alzheimer's to addressing its root causes.
 
The research also highlights the potential for Huperzine A as a safe and effective treatment. The compound is derived from a natural source and has been used in traditional medicine for centuries, with few reported side effects. This makes it a promising candidate for further clinical trials, where its efficacy in humans can be evaluated.
 
Conclusion
The study findings demonstrate that Huperzine A holds great promise in the fight against Alzheimer's disease. By regulating the amyloidogenic and nonamyloidogenic pathways and reducing tau phosphorylation, Huperzine A could potentially slow the progression of Alzheimer’s and improve cognitive function in affected individuals.
 
Further studies and clinical trials are needed to confirm these findings in humans, but the initial results are very encouraging. With Alzheimer’s disease affecting millions of people worldwide, the discovery of new treatments like Huperzine A could have a profound impact on global health.
 
The study findings were published in the peer-reviewed journal: Biology.
https://www.mdpi.com/2079-7737/13/7/518
 
 For the latest on Alzheimer’s Disease, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/contaminated-medical-products-like-growth-hormone-can-lead-to-early-onset-alzheimer-s-disease
 
https://www.thailandmedical.news/news/thailand-medical-researchers-discover-black-rice-anthocyanins-may-fight-alzheimer-s-disease